Developing an Artificial Intelligence System to Detect Mild Cognitive Impairment and Alzheimer's Disease Dementia Through Self-Figure Drawing: An Innovative Approach

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and while accepted as screening tools for AD, general practitioners seldom use them. AD can be diagnosed with expensive, invasive neuroimaging and blood tests, but these are usually conducted when cognitive functioning is already severely impaired. Thus, finding a novel, non-invasive tool to detect and differentiate mild cognitive impairment (MCI) and AD is a prime public health interest. Self-figure drawings (a projective tool in which individuals are asked to draw a picture of themselves), are easy to administer and have been shown to differentiate between healthy and cognitively impaired individuals, including AD. Convolutional Neural Network (CNN) (a type of deep neural network, applied to analyze visual imagery) has advanced to assess health conditions using art products. Therefore, the proposed study suggests utilizing CNN-based methods to develop and test an application tailored to differentiate between drawings of individuals with MCI, AD, and healthy controls (HC) using 4,000 self-figure drawings. This

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: t
View:

• Adults aged 60 and above with subtle signs of risk of future cognitive decline, residing in the community or in nursing homes with a minimum of 10 years of education.

Locations
Other Locations
Israel
University of Haifa
RECRUITING
Haifa
Contact Information
Primary
Amit Perry, MA
peryamit1@gmail.com
+9722454258
Time Frame
Start Date: 2023-03-20
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 4000
Treatments
Healthy controls
Adults aged 60 and above without cognitive impairment
Mild cognitive impairment
Adults 60 and above with mild cognitive impairment
Alzheimer's disease
Adults diagnosed with Alzheimer's disease
Related Therapeutic Areas
Sponsors
Leads: University of Haifa
Collaborators: Technion, Israel Institute of Technology

This content was sourced from clinicaltrials.gov

Similar Clinical Trials